STOCK TITAN
  1. Home
  2. News
  3. CERE

Cerevel Therapeutics Holdings Inc - CERE STOCK NEWS

IMPACT
SENTIMENT
CERE : Nasdaq
Cerevel Therapeutics to Report Third Quarter 2023 Financial Results and Business Updates on Wednesday, November 1, 2023
conferences earnings
IMPACT
SENTIMENT
CERE : Nasdaq
Cerevel Therapeutics Announces Pricing of $450 Million Public Offering of Common Stock
offering
IMPACT
SENTIMENT
CERE : Nasdaq
Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
offering
IMPACT
SENTIMENT
CERE : Nasdaq
Cerevel Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
conferences
IMPACT
SENTIMENT
CERE : Nasdaq
Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
earnings
IMPACT
SENTIMENT
CERE : Nasdaq
Cerevel Therapeutics to Report Second Quarter 2023 Financial Results and Business Updates on Wednesday, August 2, 2023
conferences earnings
IMPACT
SENTIMENT
CERE : Nasdaq
Cerevel Therapeutics Appoints Paul Burgess as Chief Business Development and Strategic Operations Officer
management
IMPACT
SENTIMENT
CERE : Nasdaq
Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer
management
IMPACT
SENTIMENT
CERE : Nasdaq
Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results
IMPACT
SENTIMENT
CERE : Nasdaq
Cerevel Therapeutics to Present at the BofA Securities 2023 Health Care Conference
conferences
Stock CERE logo
Cerevel Therapeutics Holdings Inc
Nasdaq:CERE

CERE Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About CERE

cerevel therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (cns). the company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of cns disorders, including parkinson’s, alzheimer’s, epilepsy, schizophrenia and addiction. headquartered in the greater boston area, cerevel was formed in 2018 through a partnership between bain capital and pfizer.